Home Compare AMGN vs GILD
Stock Comparison · Industry comparison · Drug Manufacturers - General

Amgen vs Gilead Sciences: Which Stock Looks Stronger in 2026?

Gilead Sciences holds the cleaner structural position, with growth as the main driver and profitability adding further support. Amgen still has the edge on growth, which keeps the comparison from looking entirely one-sided. The market setup is mixed, without a decisive signal in either direction. The market is not adding a decisive signal either way — the structural read carries the weight.

The comparison is based on similar long-term financial trajectories, not sector labels.

Updated 2026-04-05

Growth points more clearly toward Amgen Inc., even if the broader score still leans toward Gilead Sciences, Inc..

INDUSTRY COMPARISON

Both operate in: Drug Manufacturers - General

This comparison is based on industry proximity, not on functional trajectory similarity. AMGN and GILD share the same industry classification.

For a similarity-based comparison, see how Amgen and Gilead Sciences each position within their functional peer groups in AssetNext.

Peer-Relative Score
AMGN
Amgen Inc.
63
Peer-Score
Signal qualityHigh
vs
GILD
Gilead Sciences, Inc.
70
Peer-Score
Signal qualityHigh

Scores reflect position relative to comparable companies with similar long-term financial trajectories.

The largest gaps do not all point in the same direction.

Dimension spread: AMGN vs GILD Profitability 50 79 Stability 57 65 Valuation 73 83 Growth 75 44 AMGN GILD
Gap Ranking
#1 Growth +31
#2 Profitability +29
#3 Valuation +10
#4 Stability +8
Price Setup

Left means cheaper relative valuation. Higher means stronger structure.

Price setup map for AMGN and GILD Stronger + cheaper Stronger + richer Weaker + cheaper Weaker + richer AMGNGILD Relative valuation Structural strength

Structure stays fairly close here, while current pricing still looks more supportive for Gilead Sciences, Inc..

Valuation position uses peer-relative PE percentile (idx_pct_pe) where available.

Relative Position vs Comparable Companies
Growth
Both profiles are strong on growth, but Amgen Inc. leads clearly.
Profitability
On profitability, the same pattern holds: both rank well, but Gilead Sciences, Inc. still sits higher.
Growth — Dominant Gap
AMGN
75
GILD
44
Gap+31in favour of AMGN

The clearest distance comes from a stronger growth profile.

What else supports the lead

Profitability adds a second meaningful layer to the lead, with a 6.8-point operating margin advantage.

What this means for the comparison

Growth is the clearest driver of the lead, with profitability adding further support — though growth still provides a real counterweight.

Explore full peer positioning in AssetNext

Break down the AMGN vs GILD comparison across all dimensions with the full interactive tool.

Explore full breakdown →
Other comparisons with conflicting dimension signals

Explore how AMGN and GILD each compare against other companies in their peer groups.

Rule-based, descriptive analysis only. Derived from peer percentile dimensions. Not investment advice. Peer groups are determined algorithmically based on structural similarity — not by sector classification alone.

How AssetNext Peer Scores Work

AssetNext scores reflect each company's structural position within its functional peer group — not a ranking against all stocks simultaneously. Peers are identified by similarity across eight financial dimensions, including revenue growth trajectory, margin structure, capital intensity, and earnings stability. A score of 75 means the company ranks in the top quartile within its own peer group, not the entire market.

Four dimension scores drive the overall peer score: Growth (revenue trajectory and expansion dynamics), Quality (margin structure and capital efficiency), Valuation (peer-relative pricing on standard multiples), and Stability (earnings consistency and financial predictability). Each dimension is scored 0–100 relative to the peer group, then combined into an overall peer score using equal weighting.

Scores are recalculated periodically as underlying financial data is updated. All analysis is descriptive and rule-based — AssetNext describes structural realities and never issues buy, sell or hold recommendations.